Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.11 USD | -0.24% | -0.28% | -40.35% |
Jun. 03 | Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating | MT |
May. 30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.35% | 3.68B | |
+47.73% | 57.87B | |
+41.65% | 40.25B | |
-6.99% | 39.94B | |
-5.96% | 28.54B | |
+12.04% | 26.4B | |
-20.52% | 19.33B | |
+30.17% | 12.4B | |
-0.73% | 12.23B | |
+23.91% | 12.2B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours